Australia-based Admedus has received US Food and Drug Administration (FDA) clearance to market CardioCel, an advanced cardiovascular scaffold designed to repair and treat a range of cardiovascular and vascular defects.

In the US, CardioCel, a ready-to-use, off the shelf product, has now been approved for use in pericardial closure and for the repair of cardiac and vascular defects in both adults and paediatrics.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

CardioCel is engineered by the group’s ADAPT tissue engineering process to be a durable, pure collagen scaffold that avoids calcification, supports native cell infiltration, growth and differentiation and promotes a regenerative healing process.

"Researchers are exploring the use of video cameras and patented software algorithms to convert data collected by camera into vital signs."

It offers key benefits over existing products in that it does not calcify like other tissue products and has shown to facilitate autologous tissue regeneration once surgically implanted, while retaining strength and natural elasticity.

According to the company, CardioCel, the group’s lead regenerative tissue product, has the potential to prevent follow-up surgeries for patients because of its anti-calcification and regenerative properties.

Admedus CEO Lee Rodne said this is a significant milestone for the company as it expands into global markets and further develop its range of regenerative tissue products for commercialisation and sale.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"CardioCel is an important addition to the surgeon’s armoury in the treatment of congenital heart disease, as well as for the repair of heart valves and other cardiac defects," Rodne said.

CardioCel received the CE Mark allowing European launch in August 2013 and the company made its first sale there in November.

According to the company, the CE Mark allows for the repair and reconstruction of heart defects, including treating congenital heart disease and repairing heart valves in both children and adults.

In a major step for the company’s expansion into global markets, Admedus will now look to complement its existing product launch in Europe with preparation for initial sales in the US.